TG Therapeutics’ first-quarter sales of its multiple sclerosis treatment Briumvi more than doubled Wall Street’s expectations, sending TGTX stock soaring to a five-month high. The drug generated $7.8 million in sales in Q1, surpassing FactSet’s estimated $3.4 million, with more than 400 prescriptions written since the launch in January. TG Therapeutics CEO Michael Weiss said the sales “exceeded” the company’s own expectations, and the “pre-launch enthusiasm” was being reflected in the commercial setting. Briumvi is given in a one-hour infusion, twice a year, and treats relapsing forms of multiple sclerosis. TGTX shares rose 23.4% to close at $30.64.
Qualcomm’s Sobering Report Deepens Chip Market Concerns
Qualcomm, a chip designer that provides components for major handset makers such as Apple and Samsung, experienced an almost 8%...
